Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended				3 Months Ended				9 Months Ended		12 Months Ended
	Jan. 31, 2024 USD ($) shares	Jun. 30, 2023 USD ($) program shares	May 31, 2023 USD ($) program	Jul. 31, 2020 USD ($)	Sep. 30, 2024 USD ($) $ / shares	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) program	Dec. 31, 2020 USD ($)	Dec. 31, 2023 USD ($)
Related Party Transaction [Line Items]
Common stock share value						$ 228.0	$ 5.0	$ 20.0
Contract with customer, liability, revenue recognized					$ 33.0		28.0		$ 212.0	$ 79.0
Receivable from collaboration partners, current					16.0				16.0					$ 38.0
Other noncurrent assets					$ 75.0				$ 75.0					106.0
Related Party
Related Party Transaction [Line Items]
Percentage of outstanding common stock held					32.90%				32.90%
Receivable from collaboration partners, current					$ 2.0				$ 2.0					20.0
Other noncurrent assets					0.0				0.0					$ 6.0
Related Party | Research and Development
Related Party Transaction [Line Items]
Reimbursement from related party for shared costs					$ 2.0		22.0		$ 32.0	89.0
Purchase Agreement | Related Party
Related Party Transaction [Line Items]
Common stock shares issued (in shares) | shares	15.2	1.0
Common stock share value		$ 20.0
Funds received for stock purchase agreement	$ 320.0
Purchase price of common stock allocation to performance obligation	$ 87.0
Percentage of premium purchase price of common stock									20.00%
Trailing days average closing price									5 days
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares					$ 33.54				$ 33.54
Purchase Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Right to purchase additional outstanding voting common stock percentage					35.00%				35.00%
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon completion of certain IND-enabling activities												$ 60.0
Option payment upon achievement of certain development milestones												150.0
Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs													10 years
Option continuation payment due upon sixth anniversary of agreement													$ 100.0
Upfront cash payment				$ 175.0
Option fee per program for all other programs entering clinical development to exercise option												$ 150.0
Number of research programs | program												2
Contract with customer, liability, revenue recognized					$ 30.0		$ 28.0		$ 207.0	$ 82.0
Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab												$ 500.0
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs | program												3
Option payments received											$ 725.0
Removal of option continuation payment under agreement												$ 100.0
Option payment upon achievement of certain development milestones			$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments | program			2
Amended Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Upfront cash payment		$ 35.0	$ 17.5
Number of research programs | program		2
Option payment upon completion of certain IND-enabling activities			45.0
Amended Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Regulatory and commercial milestone payments received			$ 375.0